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INTRODUCTION
Intranasal meningoceles occur as a result of
herniation of the meninges into the nasal cavity through
a defect in the cribriform plate. These are commonly
found in the pediatric population due to a congenital
defect in the skull base. Intranasal meningoceles are
very rare in adults, and tend to arise only when
engendered by trauma. Here, we present the case of a
patient with seemingly unprovoked intranasal
meningocele.
CASE REPORT
Mr. M. is a 23-year-old labourer at a lignite factory
who presented with left-sided nasal obstruction and
watery discharge which he had been experiencing on-
and-off for the past 5 years. He attributed the
obstruction to a mass in his left nostril, and said he
would often breathe through his mouth. Other than an
episode of pyogenic meningitis 9 years prior to the
present complaint, this patient had been relatively
healthy. He had no history of epistaxis, head or nasal
trauma, anosmia, headache or visual disturbances.
Constitutional symptoms such as anorexia and weight
loss were absent. 
On rhinoscopic examination, the left nasal cavity was
found to contain a pale polypoidal mass with prominent
blood vessels. The mass appeared to arise from the roof
of the nasal cavity with no other points of attachment,
and almost completely obstructed the nasal cavity. It
descended to below the level of the inferior turbinate.
No active discharge was observed. In addition, there
was septal deviation to the right. 
At this point, the clinician would suspect the
following as part of the differential diagnosis:
antrochoanal polyp, inverted papilloma, angiofibroma,
intranasal menigocele, nasal glioma and congenital
tumours such as neuroblastoma (1). The clinical
presentation strongly suggested the diagnosis of polyp
for this nasal mass. 
A CT scan of the paranasal sinuses showed that they
were clear. A cystic mass attached to the roof of the
nasal cavity and causing right septal deviation could be
seen. No bone erosion was apparent, and no
abnormalities at the intracranial or orbital levels were
noted. Routine blood investigations turned out to be
normal.
TREATMENT
Due to the possibility of this nasal mass being a
meningocele, certain precautionary measures were
taken as part of endoscopic surgery to treat this patient.
Of particular importance was irrigation of the nose with
a solution of clindamycin to decrease bacteria within
the operative field so as to reduce the potential for
intracranial seeding from nasal flora. 
An aspirate of the nasal mass was taken and sent for
analysis. Rather than grasping and avulsing the mass,
the upper portion of the polyp was cut, leaving a small
sleeve. Once the mass was surgically excised, the
source of the fluid leak was closed in layers: fat, then
temporalis muscle/fascia. The temporalis fascia was
used to seal the defect and served as a scaffold for
fibrous ingrowth. Through the measurement of glucose
content of the mass aspirate, it was determined that the
fluid was cerebrospinal fluid (CSF). Pathological
analysis of the tissue was characteristic of the
meninges. These two findings correlated with the
diagnosis of intranasal meningocele.
Post-operative management of this patient consisted
of antibiotics (amoxicillin/clavulinic acid),
acetazolamide and bedrest in the head-up position. The
nasal pack was removed after 5 days. Diagnostic32 McGill Journal of Medicine 2006
endoscopy on the 7th post-operative day showed that
the graft was in place. No CSF leak was observed, and
the patient did not complain of rhinorrhea subsequent to
surgery.
DISCUSSION
Intranasal meningocoeles occur secondary to
meningeal herniation through a defect in the floor of the
anterior cranial fossa. In addition, there is a disruption
in the arachnoid and dura mater, leading to a CSF leak.
In a patient with intranasal meningocele, this is
manifested as CSF rhinorrhea (2). 
A CSF pressure gradient that is greater than the
tensile strength of the disrupted tissue is a contributing
factor in meningeal herniation. This can occur in the
context of intracranial hypertension and results in
exertion of hydrostatic pressure at anatomically
weakened sites within the skull base (3). When elevated
intracranial pressure is present, the weakest anatomic
points in the periphery of the central nervous system
(optic nerve sheath, the cribriform plate, the sellar
diaphragm, and any other bony dehiscences in the
anterior or middle cranial fossae) can act as potential
release valves for the high pressure (4).
There are various possible etiologies of CSF leaks:
spontaneous, accidental trauma, surgical trauma,
congenital, and tumours.
The most common etiology of CSF leaks is accidental
trauma from closed head injury; such leaks occur in
around 1% to 3% of all closed head injuries. In such
instances, CSF leaks usually begin within 48 hours, and
95% of them manifest within 3 months of injury (5). 
The detection of CSF fistulae is best made these days
using Computed Tomographic Cisternography (CTC)
(5). Such instrumentation is not readily available in
hospitals of developing countries, thus the visualization
and detection of herniation in this case was made using
CT scanning.
Other methods used to localize CSF leakage include
plain skull films, positron emission tomography,
introduction of dyes by lumbar puncture, digital
fluoroscopy and magnetic resonance imaging (5). 
Intraoperatively, one can identify the site of a leak
through the immunoelectrophoretic identification of
CSF-specific marker proteins such as B2-transferrin.
The sodium fluorescein test perioperatively enables
precise localization of the defect and allows for
confirmation of complete sealing of the leak (6).
Intranasal meningocele can be complicated by
meningitis, as the intracranial contents are exposed to
intranasal organisms such as S. pneumoniae and H.
influenzae.
The patient's own episode of pyogenic meningitis 9
years ago was likely attributable to such a
communication with intranasal contents. Intranasal
meningoceles, as mentioned earlier, present most
commonly in childhood as the result of a congenital
weakness in the cribriform plate. It is probable that our
patient had such congenital weakness to a lesser extent
than most individuals. It is also possible that some
minor trauma contributed to herniation through a pre-
existing weak cribriform plate. The herniation through
the cribriform plate defect was likely minimal when the
patient suffered an episode of pyogenic meningitis,
which might be why the patient did not feel nasal
obstruction at the time. 
Surgical repair of CSF leak using a frontal
craniotomy approach was started by Dandy in 1926.
This was followed by extracranial and transnasal
approaches in the 1950s. Endoscopic technique, which
was being used principally for sinus surgery, was first
attempted in the repair of CSF leaks in 1981 (8, 9). This
has evolved to the present-day endoscopic technique
which offers greater benefits by way of visualization, no
scar remnant, lower morbidity and no adverse effect on
the sense of smell. The literature shows that the success
rate with such an approach is 86 to 97% (10, 11). 
Certain medical centers in the U.S. have begun to
implement computer-assisted image-guided surgery
techniques, which have ensured more accurate and
precise closure of cribriform plate defects.
With respect to post-operative management, nasal
packing is kept in place in order to compress the fascia
against the recipient bed. Bedrest in the head-up
position ensures that CSF pressure at the anterior skull
base is decreased. Acetazolamide is used to decrease
ICP, thus preventing herniation. It is a diuretic that
diminishes CSF production by 48% (12).
In summary, patient presentation with nasal mass and
rhinorrhea has its own set of differential diagnoses.
Intranasal meningocele, although relatively rare, comes
under this differential. CSF rhinorrhea is a diagnostic
challenge; if not recognized, it can lead to devastating
complications.
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